<DOC>
	<DOCNO>NCT00647192</DOCNO>
	<brief_summary>The purpose study determine whether Eplerenone reduce atrial fibrillation ( AF ) recurrence within first 8 week electrical cardioversion persistent AF .</brief_summary>
	<brief_title>EPLERAF-Study : Eplerenone Prevention Atrial Fibrillation Recurrences After Cardioversion</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Persistent atrial fibrillation ( AF ) , AF persistence &gt; 7 day &lt; 1 year Total AF history &lt; 2 year Written inform consent patient Age ≥18 year Female patient sterilise postmenopausal apply adequate method contraception ( Pearl index &lt; 1 % ) negative pregnancy test ( ßHCG ) breastfeed/nurse . Hemodynamic instability symptom allow cardioversion delay 3 week Myocardial infarction within last 3 month Heart failure NYHA class III IV Uncontrolled hypertension , define systolic blood pressure &gt; 160 mm Hg and/or diastolic blood pressure &gt; 95 mm Hg ( antihypertensive treatment allow ) . Pretreatment aldosterone antagonist potassium spar diuretic Instable angina pectoris Use Digitalis Use class I class III antiarrhythmic drug ( must stop least 5 halflife ) Contraindication hypersensitivity ßblockers Open heart surgery within last 3 month Pregnancy Acute reversible illness Acute chronic infection Alcohol drug abuse severe progressive extracardiac disease Untreated manifest latent hyper hypothyroidism &lt; 3 month peripheral euthyroidism ( normal fT3 ) Moderate severe renal insufficiency ( Creatinine clearance le 50 ml/min ) Patients liver cirrhosis ( ChildPugh class C ) Coadministration strong CYP3A4 inhibitor ( e.g . Itraconazole , Ketoconazole , Ritonavir , Nelfinavir , Clarithromycin , Telithromycin Nephazodon ) Hypersensitivity Eplerenone and/or one component tablet ( see Fachinformation ) Serum potassium &gt; 5 mmol/l Patients unlikely comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>atrial fibrillation</keyword>
	<keyword>electrical cardioversion</keyword>
	<keyword>prevention atrial fibrillation recurrence</keyword>
	<keyword>mineralocorticoid receptor blocker</keyword>
	<keyword>eplerenone</keyword>
	<keyword>Recurrence atrial fibrillation cardioversion</keyword>
</DOC>